1. Home
  2. CYTK vs CRL Comparison

CYTK vs CRL Comparison

Compare CYTK & CRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

HOLD

Current Price

$64.98

Market Cap

7.6B

Sector

Health Care

ML Signal

HOLD

Logo Charles River Laboratories International Inc.

CRL

Charles River Laboratories International Inc.

HOLD

Current Price

$175.51

Market Cap

7.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CYTK
CRL
Founded
1997
1947
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Commercial Physical & Biological Resarch
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.6B
7.5B
IPO Year
2004
1999

Fundamental Metrics

Financial Performance
Metric
CYTK
CRL
Price
$64.98
$175.51
Analyst Decision
Strong Buy
Buy
Analyst Count
18
12
Target Price
$88.94
$200.09
AVG Volume (30 Days)
1.8M
792.1K
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$13,368,000.00
$1,857,601,000.00
Revenue This Year
$6.88
$0.19
Revenue Next Year
$308.26
$2.98
P/E Ratio
N/A
N/A
Revenue Growth
N/A
10.48
52 Week Low
$29.31
$99.80
52 Week High
$70.98
$228.88

Technical Indicators

Market Signals
Indicator
CYTK
CRL
Relative Strength Index (RSI) 54.07 56.95
Support Level $59.12 $146.49
Resistance Level $67.94 $182.76
Average True Range (ATR) 2.25 6.94
MACD 0.26 2.31
Stochastic Oscillator 61.73 81.77

Price Performance

Historical Comparison
CYTK
CRL

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About CRL Charles River Laboratories International Inc.

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Share on Social Networks: